THE PATTERN OF CARDIOVASCULAR COMORBIDITY IN PATIENTS WITH SEVERE FORMS OF PSORIASIS: DATA OF RETROSPECTIVE ANALYSIS OF A HOSPITAL COHORT

Psoriasis (Ps) and psoriatic arthritis (PsA) are, in addition to skin and osteoarticular lesions, accompanied by a variety of comorbidities, primarily cardiovascular diseases (CVDs), which contributes to shorter life expectancy by on an average of 5–7 years. There are scarce data on the prevalence and pattern of CVDs in a Russian cohort of patients with severe forms of Ps and PsA. Obtaining such information can contribute to the elaboration of programs for screening and prevention of CVDs in this patient group.

Objective: to study the prevalence and pattern of CVDs in a hospital cohort of patients with severe forms of Ps and PsA.

Subjects and methods. Medical records were retrospectively analyzed in 890 patients with severe forms of Ps (mean age, 51.9±11.6 years; mean Ps duration, 11.6±0.6 years); who had been treated at the Branch of the V.G. Korolenko Clinic, Moscow Research and Practical Center of Dermatovenereology and Cosmetology, in 2010 to 2015. The Psoriasis Area and Severity Index (PASI) averaged 49.4±0.5. The frequency of PsA was assessed by the code L40.5; that of SVDs was determined by the registered diagnoses in accordance with the codes of the International Classification of Diseases, 10th edition (ICD-10): hypertension (ICD-10 code I10–I15), coronary heart disease (CHD) (I20–I25), atherosclerosis (I70), and cerebrovascular disorders (I65–I66).

Results and discussion. PsA was identified in 303 (34%) patients. There were a total of 516 (59%) patients with CVDs. Hypertension, CHD, atherosclerosis, and cerebrovascular disorders were more frequently recorded in patients with PsA than in those with PsA without arthritis.

Conclusion. CVDs are recorded in more than half of the hospital cohort patients with severe forms of Ps. CVDs are more frequently recorded in PsA than in Ps without arthritis. Hypertension among the SVDs is a leader in its frequency in both groups; more than half of the patients were found to have CHD and atherosclerosis; cerebrovascular disorders were less common.

1. Machado-Pinto JM, Diniz MS, Bavoso NC. Psoriasis: new comorbidities. Ann Bras Dermatol. 2016;91(1):8-16. doi: 10.1590/abd1806-4841.20164169

2. Masson W, Rossi E, Galimberti ML, et al. Mortality in patients with psoriasis. A retrospective cohort study. Med Clin (Barc). 2017;148(11):483-8. doi: 10.1016/j.medcli.2016.12.011

3. Маркелова ЕИ, Коротаева ТВ, Новикова ДС и др. Распространенность метаболического синдрома у больных псориатическим аритритом: его связь с воспалением и субклиническим атеросклерозом. Научно-практическая ревматология. 2016;54(Прил 1):20-4 [Markelova EI, Korotaeva TV, Novikova DS, et al. Prevalence of metabolic syndrome in patients with psoriatic arthritis: Its association with inflammation and subclinical atherosclerosis. Nauchno- Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54 Suppl. 1:20-4 (In Russ.)]. doi: 10.14412/1995-4484-2016-1S-20-24

4. Eder L, Zisman D, Barzilai M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case control study. J Rheumatol. 2008;35:877-82.

5. Augustin M, Vietri J, Tian H, et al. Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. J Eur Acad Dermatol Venereol. 2017 Apr 20. doi: 10.1111/jdv.14286

6. Bengtsson K, Forsblad-d'Elia H, Lie E, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017 May 18;19(1):102. doi: 10.1186/s13075-017-1315-z

7. Ding HS, Yang J, Jang J, et al. Interleukin-17 contributes to cardiovascular diseases. Mol Biol Rep. 2012;39(7):7473-8. doi: 10.1007/s11033-012-1580-5

8. Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-96. doi: 10.1038/jid.2010.103

9. Mehta NN, Yu Yi, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (FDG-PET/CT). Arch Dermatol. 2011;147(9);1031-9. doi: 10.1001/archdermatol. 2011.119

10. Ogdie A, Haynes K, Troxel AB, et al. The risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. Ann Rheum Dis. 2014,73(1):149-53. doi: 10.1136/annrheumdis-2012-202424

11. Malbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatient. Eur J Epidemiol. 2004;19:225-30. doi: 10.1023/B:EJEP.0000020447.59150.f9

12. Marshall V, Farah M, Hawkins S, et al. Cardiovascular Disease Outcomes Associated with Three Major Inflammatory Dermatologic Diseases: A propensity-matched case control study. Dermatol Ther (Heidelb). 2016;6:649-58. doi: 10.1007/S13555-016-0144-3

13. Qureshi A, Choi HK, Curhan GC. Psoriasis and the risk of diabetes and hypertension – a prospective study of US female nurses. Arch Dermatol. 2009;145(4):379-82. doi: 10.1001/archdermatol.2009.48

14. Augustin M, Reich K, Glaeske G, et al. Co-morbidity and agerelated prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90(2):147-50. doi: 10.234/00015555-0770

15. Takeshita J, Wang S, Shin DB, et al. Effect of Psoriasis Severity on Hypertension Control: A population-based study in the United Kingdom. JAMA Dermatol. 2015;151(2):161-9. doi: 10.1001/jamadewrmatol.2014.2094

16. Cohen AD, Weitzman D, Dreiher J, et al. Psoriasis and hypertension: a case control study. Acta Derm-Venerol. 2010;90(1):23-6. doi: 10.2340/00015555-0741

17. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and metaanalysis of observational studies. J Hypertens. 2013;31(3):433-43. doi: 10.1097/HJH.0b013e32835bcce1

18. Reich K, Mrowietz U, Radtke MA, et al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875- 83. doi: 10.1007/s00403-015-1593-8

19. Karbach S, Croxford AL, Oelze M, et al. Interleukin 17 drives vascular inflammation, endothelial dysfunction and artherial hypertension in psoriasis-like skin disease. Atheroscler Thromb Vasc Biol. 2014;34(12):230-6. doi: 10.1161/ATVBBAHA.114.304108

20. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritits inpatients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-35. doi: 10.1016/jaad.2013.07.023

21. Чамурлиева МН, Логинова ЕЮ, Коротаева ТВ и др. Поражение костно-суставного аппарата у больных псориазом по данным скринингового опросника PEST (Psoriasis Epydemiology Screening Tool) и ревматологического клинико-инструментального обследования. Научно-практическая ревматология. 2014;52(6):636-42 [Chamurlieva MN, Loginova EYu, Korotaeva TV, et al. Osteoarticular injury in psoriatic patients according to the data of PEST (Psoriasis Epidemiology Screening Tool) questionnaire and rheumatological clinicoinstrumental examination. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(6):636-42 (In Russ.)]. doi: 10.14412/1995- 4484-2014-636-642

22. Choi JW, Kim BR, Youn SW. Could psoriatic arthritits be easily diagnosed from current suspicious physical findings in dermatology clinic? Ann Dermatol. 2017;29(1):48-54. doi: 10.5021/ad.2017.29.1.48

23. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013 Jan;149(1):84-91. doi: 10.1001/2013.jamadermatol.406

24. Dogan S, Atakan N. Psoriasis: A disease of systemic inflammation with comorbidities. In: Lima H, editor. Psoriasis – Types, Causes and Medication. InTech; 2013. Avalable from: http://www.intechopen.com/books/psoriasis-types-causes-andmedication/psoriasis-a-disease-of-systemic-inflammation-withcomorbidities

25. Frers KRA, Bisoendial RJ. Montoya SF, et al. Psoriasis and cardiovascular risk: Immune- mediated crosstalk between metabolic, vascular and autoimmune inflammation. IJC Metabol Endocr. 2015;6:43-54. doi: 10.1016/j.ijcme.2015.01.005

26. Sundarrajan S, Arumugam M. Comorbidities of psoriasis-exploring the links by network approach. PLoS ONE. 2016;11(3):e0149175. doi: 10.1371/journal.pone.0149175

27. Gulliver WP. Genetic targets for the future treatment of psoriasis including HLA-Cw6. Presented at: 21st World Congress of Dermatology, 30 September – 5 October 2007, Buenos Aires, Argentina.

28. O'Reilly DD, Rahman P. Genetic, epigenetic and pharmacogenetic aspects of psoriasis and psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):623-42. doi: 10.1016/j.rdc.2015.07.002

29. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197-204. doi: 10.1111/j.1365-2796.2012.02593.x

30. Roubille C, Richer V, Starnino T, et al. The effects of tumor necrosis factor inhibitors, methotrexate, non-steroidal antiinflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-9. doi: 10.1136/annrheumdis-2014-206624

31. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341-4. doi: 10.1111/j.1468-3083.2007.02429.x

32. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol. 2007;87:506-9. doi: 10.2340/00015555-0297

33. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493-9. doi: 10.1001/archderm.143.12.1493